Second-Line Treatment After Concerta for Adult ADHD
After Concerta (methylphenidate extended-release) fails or is not tolerated in adults with ADHD, switch to lisdexamfetamine as the preferred second-line option, or use atomoxetine if stimulants are contraindicated or not tolerated.
Primary Second-Line Options
Lisdexamfetamine (Preferred Stimulant Alternative)
- Lisdexamfetamine is the optimal second-line stimulant when methylphenidate proves inadequate 1
- This prodrug has a 12-hour duration with slow onset, minimizing abuse potential compared to other amphetamines 1
- In adults switching from methylphenidate, lisdexamfetamine demonstrates superior adherence (proportion of days covered: 0.48 vs 0.30 for atomoxetine at 12 months) and lower discontinuation rates (63% vs 85%) 2
- Amphetamines including lisdexamfetamine have the most robust efficacy evidence among alternative ADHD treatments 3
Atomoxetine (Preferred Non-Stimulant)
- Atomoxetine serves as the primary second-line option when stimulants cannot be used 4
- This is the only FDA-approved non-stimulant with extensive efficacy data in adult ADHD 4
- Use atomoxetine specifically when:
- Stimulants are contraindicated (cardiac disease, substance abuse history, severe anxiety)
- Patient experienced intolerable stimulant side effects
- Patient preference for non-stimulant therapy
- Atomoxetine has lower adherence and higher discontinuation compared to lisdexamfetamine, but remains effective for those who cannot use stimulants 2
Clinical Decision Algorithm
Step 1: Assess why Concerta failed
- Inadequate response despite optimal dosing (up to 72 mg/day) 5
- Intolerable side effects (cardiovascular, psychiatric, appetite suppression)
- Contraindications emerged (cardiac abnormalities, uncontrolled hypertension, psychosis) 5
Step 2: Screen for contraindications to alternative stimulants
- Cardiac evaluation: structural abnormalities, cardiomyopathy, arrhythmias, coronary disease 5
- Psychiatric screening: active psychosis, bipolar disorder (risk of manic induction), severe anxiety 5
- Substance use history: current or recent stimulant abuse
- Blood pressure and heart rate monitoring 5
Step 3: Choose second-line agent
If no stimulant contraindications exist: Switch to lisdexamfetamine
- Start 30 mg daily, titrate weekly to maximum 70 mg
- Expect similar efficacy to methylphenidate with potentially different side effect profile
If stimulant contraindications present: Switch to atomoxetine
- Start 40 mg daily, increase after minimum 3 days to target 80-100 mg daily
- Full therapeutic effect may take 4-6 weeks (unlike stimulants)
- Monitor for hepatotoxicity, though rare
Additional Second-Line Considerations
Other Non-Stimulant Options
When both lisdexamfetamine and atomoxetine fail or are contraindicated 4:
- Bupropion: Particularly useful with comorbid depression; avoid in seizure disorders or eating disorders
- Guanfacine extended-release: Consider with comorbid tic disorders or when blood pressure reduction is beneficial
- Tricyclic antidepressants: Reserve for refractory cases; requires cardiac monitoring
Critical Safety Monitoring
For all stimulant switches:
- Blood pressure and heart rate at each visit 5
- Screen for emergence of psychotic symptoms or mania 5
- Monitor for priapism (rare but requires immediate attention) 5
- Assess for peripheral vasculopathy including Raynaud's phenomenon 5
Common pitfall: Assuming all methylphenidate formulations are equivalent. Concerta's OROS delivery system provides ascending plasma levels over 12 hours 6. When switching to lisdexamfetamine, the pharmacokinetic profile differs significantly, requiring individualized dose finding.
Avoid: Combining multiple stimulants simultaneously or using MAO inhibitors within 14 days of any stimulant 5.
Evidence Strength Considerations
The recommendation prioritizes lisdexamfetamine over atomoxetine as second-line based on the 2016 head-to-head comparison showing superior real-world adherence and persistence 2. However, atomoxetine remains the guideline-endorsed second-line option when stimulants must be avoided 4. The 2024 Asian guidelines confirm this hierarchy, noting atomoxetine as second-line after methylphenidate failure in Taiwan specifically 7.
The evidence for adult ADHD second-line treatment is less robust than pediatric data, with most high-quality studies focusing on first-line options. Clinical judgment regarding comorbidities, prior response patterns, and patient-specific risk factors becomes particularly important in second-line selection.